Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITRO-DUR vs MONOKET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitroglycerin is a prodrug that is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylyl cyclase, increasing c GMP, leading to vasodilation primarily in veins and arteries.
Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular c GMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Prophylaxis and treatment of angina pectoris due to coronary artery disease,Heart failure (IV formulation),Hypertensive crisis (IV formulation),Anal fissures (topical ointment)
Prevention of angina pectoris due to coronary artery disease,Off-label: treatment of chronic stable angina in combination with beta-blockers or calcium channel blockers
Transdermal: Initial 0.2-0.4 mg/h applied once daily, titrate to 0.4-0.8 mg/h; maximum 0.8 mg/h. Remove for 10-12 hours daily to prevent tolerance.
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.
2–3 minutes (nitroglycerin); prolonged to ~30 minutes for active metabolites. Clinical context: Requires frequent dosing or continuous administration for sustained effect.
Terminal elimination half-life is approximately 5 hours (range 4–6 hours) for isosorbide mononitrate, consistent with a sustained duration suitable for once-daily dosing.
Metabolized by glutathione S-transferases (GSTs) in the liver and erythrocytes, producing glycerol dinitrate and nitrite ions.
Primarily hepatic metabolism via denitration; no significant cytochrome P450 involvement. Metabolites include isosorbide and isosorbide-2-mononitrate (active).
Primarily renal (>80% as inactive metabolites; <1% unchanged nitroglycerin). Minor biliary/fecal elimination.
Renal: approximately 98% of the dose is excreted in urine as metabolites (isosorbide mononitrate and its glucuronide conjugates); fecal excretion is minimal (<2%).
~60% (mainly to albumin).
Isosorbide mononitrate is less than 5% bound to plasma proteins.
~3 L/kg (extensive tissue distribution).
Volume of distribution is approximately 0.6 L/kg (range 0.5–0.7 L/kg), indicating distribution primarily into total body water and well-perfused tissues.
Transdermal: ~70% (relative to IV). Oral: <10% (extensive first-pass metabolism).
Oral: nearly 100% (complete absorption with no significant first-pass metabolism, as isosorbide mononitrate is the active metabolite of isosorbide dinitrate).
No dose adjustment needed for any degree of renal impairment.
No adjustment required for mild to moderate renal impairment. For severe renal impairment (e GFR <30 m L/min/1.73 m²), use with caution and monitor for hypotension.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Use with caution, consider dose reduction by 25-50% due to reduced metabolism. Child-Pugh Class C: Avoid use or use minimal effective dose (e.g., 0.2 mg/h) with close monitoring.
No specific adjustment for Child-Pugh A or B. For Child-Pugh C, dose reduction is recommended; initial dose 10 mg once daily and titrate carefully.
Safety and efficacy not established in pediatric patients; no standard dosing guidelines.
Safety and efficacy have not been established in pediatric patients (age <18 years).
Start at low end of dosing range (0.2 mg/h), titrate slowly, monitor for hypotension and dizziness. Increased sensitivity due to age-related vascular changes; may require extended nitrate-free interval (e.g., 12-14 hours).
Start at the low end of the dosing range (20 mg once daily) due to increased sensitivity to hypotension and fall risk; titrate slowly.
Do not use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) due to risk of severe hypotension.
NOT for use in acute myocardial infarction or acute episodes of angina. Do not use with phosphodiesterase-5 (PDE5) inhibitors (e.g., sildenafil, tadalafil) due to risk of severe hypotension.
Hypotension, especially in hypovolemic patients; tolerance with chronic use; paradoxical bradycardia and increased angina; exacerbate hypertrophic cardiomyopathy; avoid abrupt discontinuation.
Hypotension, especially during initial dosing or dose escalation; tolerance development with prolonged use (intermittent dosing required); exacerbation of angina upon abrupt withdrawal; use with caution in patients with volume depletion, hypotension, or hypertrophic cardiomyopathy.
Concomitant use with PDE-5 inhibitors; severe anemia; increased intracranial pressure; hypersensitivity to nitroglycerin; acute circulatory failure; constrictive pericarditis; pericardial tamponade.
Concomitant use with PDE5 inhibitors (e.g., sildenafil, tadalafil, vardenafil); severe hypotension (systolic BP <90 mm Hg); hypovolemia; increased intracranial pressure; acute myocardial infarction with low filling pressures; severe anemia.
Avoid alcohol, as it can enhance hypotensive effects. No specific food restrictions, but high-fat meals may delay absorption of nitroglycerin if administered orally; transdermal route is less affected.
No significant food interactions. However, alcohol should be avoided due to additive vasodilation and hypotension.
FDA Pregnancy Category C. First trimester: Animal studies show fetal harm, but no adequate human studies; potential risk cannot be ruled out. Second and third trimesters: Possible fetal bradycardia, hypotension, and reduced placental perfusion; avoid near term due to risk of maternal hypotension and fetal distress.
Isosorbide mononitrate (MONOKET) is a nitrate vasodilator. Animal studies show no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. However, nitrates can cause uterine relaxation, potentially affecting labor. Use only if clearly needed, with caution in the third trimester due to risk of maternal hypotension and reduced placental perfusion.
Excreted in breast milk; M/P ratio not established. Use with caution, monitor infant for hypotension or methemoglobinemia; consider pump and discard if high doses used.
It is not known whether isosorbide mononitrate is excreted into human breast milk. The M/P ratio is not available. Because many drugs are excreted in human milk, caution should be exercised when MONOKET is administered to a nursing woman. Consider the importance of the drug to the mother and potential risk to the infant.
No specific dose adjustments recommended; however, increased plasma volume may reduce drug concentrations; titrate to effect, avoid hypotension to maintain placental perfusion.
No specific pharmacokinetic data for pregnancy requiring dose adjustments. However, pregnancy-induced hemodynamic changes (increased blood volume, cardiac output) may theoretically alter response. Use the lowest effective dose to avoid maternal hypotension. Taper the dose gradually if discontinuing to prevent rebound ischemia.
NITRO-DUR (nitroglycerin) transdermal patch is used for angina prophylaxis, not acute attacks. Apply to hairless area, avoid chest if possible to prevent interference with defibrillation. Rotate sites daily to prevent tolerance; remove patch for 10-12 hours daily to maintain nitrate-free interval. Contraindicated with PDE5 inhibitors (sildenafil, tadalafil, vardenafil) due to risk of severe hypotension. Monitor for hypotension, reflex tachycardia, headache.
Monoket (isosorbide mononitrate) is a long-acting nitrate used for angina prophylaxis, not acute attacks. Tolerance develops with sustained use; use a daily nitrate-free interval of 10-14 hours. Avoid in hypertrophic cardiomyopathy, aortic stenosis, and with phosphodiesterase-5 inhibitors (risk of severe hypotension). Headache is common initially but often subsides.
Apply patch once daily to clean, dry, hairless skin on upper arm, chest, or back.,Remove old patch before applying new one.,Keep patch on for 12-14 hours then remove for 10-12 hours to prevent tolerance.,Do not use during acute angina attack; use sublingual nitroglycerin instead.,Avoid alcohol and erectile dysfunction drugs (Viagra, Cialis, Levitra) while using this patch.,Common side effects: headache, dizziness, flushing. Report severe headache or fainting.,Do not stop abruptly; may cause rebound angina.
Take this medication exactly as prescribed to prevent angina attacks, not to relieve an attack already occurring.,Do not take with erectile dysfunction drugs (like sildenafil, tadalafil) — can cause dangerous blood pressure drop.,Headaches may occur initially but often improve with continued use; consult your doctor if persistent.,Avoid alcohol as it may worsen side effects like dizziness and hypotension.,If you miss a dose, skip it; do not double the next dose. Maintain a consistent dosing schedule with a nitrate-free period.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITRO-DUR vs MONOKET, answered by our medical review team.
NITRO-DUR is a Nitrate Vasodilator that works by Nitroglycerin is a prodrug that is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylyl cyclase, increasing c GMP, leading to vasodilation primarily in veins and arteries.. MONOKET is a Nitrate Vasodilator that works by Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular c GMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITRO-DUR and MONOKET depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITRO-DUR is: Transdermal: Initial 0.2-0.4 mg/h applied once daily, titrate to 0.4-0.8 mg/h; maximum 0.8 mg/h. Remove for 10-12 hours daily to prevent tolerance.. The standard adult dose of MONOKET is: 20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITRO-DUR and MONOKET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITRO-DUR is classified as Category C. FDA Pregnancy Category C. First trimester: Animal studies show fetal harm, but no adequate human studies; potential risk cannot be ruled out. Second and third trimesters: Possible . MONOKET is classified as Category C. Isosorbide mononitrate (MONOKET) is a nitrate vasodilator. Animal studies show no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. H. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.